Precision medicine plays a transformative and increasingly central role in the treatment of non-Hodgkin’s lymphoma (NHL) by tailoring therapies to the unique genetic, molecular, and immunologic characteristics of each patient’s cancer. Unlike traditional one-size-fits-all approaches, precision medicine leverages detailed information…
Dementia-like symptoms can indeed appear in advanced non-Hodgkin’s lymphoma, although this is not the most common presentation and is often related to specific complications or involvement of the nervous system by the lymphoma. Understanding how and why these symptoms arise…
Non-Hodgkin’s lymphoma (NHL) research addressing brain involvement focuses on understanding how lymphoma affects the central nervous system (CNS), improving diagnosis, and developing effective treatments that minimize neurological damage. Brain involvement in NHL can occur either as primary CNS lymphoma (PCNSL),…
Older adults **can access clinical trials for non-Hodgkin’s lymphoma (NHL) research**, though their participation depends on specific eligibility criteria set by each trial. Many clinical trials for NHL include adults aged 18 and older, with no strict upper age limit,…
T-cell therapies, particularly CAR T-cell therapy, have become a transformative approach in the care of non-Hodgkin’s lymphoma (NHL), especially for patients with relapsed or refractory disease who have exhausted conventional treatments. These therapies harness the power of the patient’s own…
Non-Hodgkin’s lymphoma (NHL) is a complex group of blood cancers originating in the lymphatic system, primarily affecting B-cells. Treatment has traditionally relied on chemotherapy, radiation, and more recently, targeted therapies. While these treatments can be effective in controlling or even…
Measuring the quality of life (QoL) in survivors of non-Hodgkin’s lymphoma (NHL) is a complex but essential task that helps researchers and clinicians understand how the disease and its treatments affect patients beyond just clinical outcomes. Quality of life encompasses…
Machine learning has significant potential to improve the detection of relapse in non-Hodgkin’s lymphoma (NHL) by leveraging complex data patterns that traditional methods may miss. NHL is a diverse group of blood cancers originating in lymphocytes, and relapse detection is…
Immune checkpoint inhibition plays a significant and evolving role in the treatment of non-Hodgkin’s lymphoma (NHL), a diverse group of blood cancers originating from lymphocytes. The immune system naturally has built-in “checkpoints”—molecules on immune cells that act like brakes to…
Dementia can significantly complicate treatment decisions for patients diagnosed with non-Hodgkin’s lymphoma (NHL) because it affects cognitive function, decision-making capacity, and overall health status. Non-Hodgkin’s lymphoma is a type of cancer that originates in the lymphatic system, and its treatment…